Each “no” or “unsure” is an item to raise at your next appointment.
0 of 9 answered
Disease Phase
What it is: Your disease is either active (curvature still progressing) or stable (curvature unchanged for ≥3 months). This is NOT determined by how long you've had PD or whether your pain has reduced. The only criterion is whether curvature is still changing.
Why it matters: The older "12-18 month acute phase" framing has been formally abandoned (ICSM 2024). Phase determines treatment options — surgery requires stable phase ≥6 months; non-surgical options open at ≥3 months stable; CCH is viable in active phase per current evidence.
Your situation
Research finds
Source
Active (regardless of pain trajectory)
CCH viable — active phase is NOT a barrier (P=.48 NS)
Cahill 2025 (n=826); Cocci 2020 (n=74)
Active with pain reducing
Pain reduction does NOT confirm stability — curvature progression is the criterion
ICSM 2024
Active at >18 months
Documented existence-proof: active disease at 22-26 months with pain already resolved
Paulis 2024 (n=564)
Stable (≥3 months no curvature change)
All non-surgical treatment options available
ICSM 2024
Stable (≥6 months)
Surgical reconstruction option opens
ICSM 2024 Rec
Curvature Type + Degree
What it is: The direction your penis curves (dorsal=upward, ventral=downward, lateral=sideways, complex=multi-direction) and the angle in degrees at maximum deviation, measured during Doppler.
Why it matters: Both direction and degree are independent predictors of treatment response. Direction predicts CCH responsiveness. Greater baseline curvature predicts greater absolute improvement (Cahill 2025: 0.5° more improvement per 1° baseline, P<.0001; Flores 2022: OR 1.33 per 10°).
Your situation
Research finds
Source
Dorsal (upward)
Among the better-responding directions: ~50% median improvement (50.09%)
Lumbiganon 2025 (n=292)
Ventrolateral
Comparable to dorsal: ~50.72% median improvement
Lumbiganon 2025
Multi-direction (complex)
Highest response in the cohort: ~56% median improvement
Lumbiganon 2025
Ventral (downward)
Lower response: ~33.57% median improvement
Lumbiganon 2025
Lateral (sideways)
-11.2° worse outcomes overall (multivariate)
Cahill 2025 (n=826, P<.001)
Under 30°
Often managed with observation alone
Guide / ICSM 2024
30-60°
Core CCH and traction treatment range
Guide / Flores 2022
Over 60°
May require surgical evaluation
Guide / ICSM 2024
Plaque Calcification
What it is: Whether your PD plaque contains calcium deposits, and how dense they are (stippled = scattered, dense = solid, absent = none). Often NOT documented on Doppler reports.
Why it matters: Calcification has been historically over-cited as a barrier to CCH treatment. The largest published outcomes data does NOT support this — Cahill 2025 (n=826, P=.37) found no significant association between calcification and treatment failure. Even if calcification IS present, CCH remains viable.
Your situation
Research finds
Source
Absent or stippled
Slightly better CCH response (OR 2.50 for noncalcified)
Wymer 2018 (n=115, retrospective)
Dense
Calcified patients CAN still improve substantially with CCH (-17.5°)
Masterson 2023 (n=47, prospective per PubMed abstract)
Not assessed / not graded
Documentation gap — not a clinical barrier. Largest series (n=826) found no association with CCH failure (P=.37). Worth resolving at follow-up.
What it is: Hourglass narrowing, focal indentation, distal tapering, or axial instability (bending/wobbling during erection). Often patient-noticed but clinically under-assessed.
Why it matters: 65% of PD patients have one of these (Margolin 2018, n=128) — yet routine PD evaluation often doesn't formally assess for them. The historical assumption was that hourglass deformity limited treatment options. The largest published CCH outcomes study (Cahill 2025, n=826) found the opposite: moderate or severe hourglass / indentation predicts MORE CCH improvement, not less.
Your situation
Research finds
Source
No volume-loss deformity
Treatment proceeds per other variables
Margolin 2018 (n=128)
Hourglass or indentation, moderate/severe
3-10° MORE CCH improvement than absent/mild (counter to historical assumption)
Margolin 2018 (after controlling for curvature angle)
Self-noticed but not formally assessed
Documentation gap; ask for assessment — may unlock favorable CCH subgroup status
Margolin 2018 (assessment gap is systemic)
Severe deformity (when surgery on the table)
Extra-tunical grafting (ETG) viable: 94.1% satisfaction, 11.8% mild hypoesthesia, zero ED worsening
Reed-Maldonado 2018 (n=17)
Erectile Function
What it is: Doppler vascular flow measurements (peak systolic, end-diastolic, time-to-peak, venous closure) plus erectile response with pharmacological injection.
Why it matters: Doppler resolves whether erectile difficulty is vascular (blood-flow problem), PD-secondary (caused by curvature/anxiety), or psychogenic. 56.4% of PD patients with ED had ED BEFORE developing PD (Paulis 2024) — so the cause matters for treatment.
Your situation
Research finds
Source
Normal vascular flow + venous closure
Vascular cause of ED ruled out; ED if present is PD-secondary or psychogenic
Paulis 2024
Strong erectile response (>80%)
Most non-surgical treatments remain viable
Goldstein 2017
Weak erectile response
Treatment conversation may shift toward combined PD + ED management
AUA 2015
Vascular abnormality
Treat ED separately as well as PD
ICSM 2024
Treatment Protocol / History
What it is: Your current PD treatment regimen — what's being injected, what's being prescribed, and on what schedule (e.g., verapamil monthly, CCH 4-cycle protocol, RestoreX traction daily).
Why it matters: Different PD treatments have radically different evidence bases. The only double-blind RCT of intralesional verapamil (Favilla 2017, n=140) found 0.00° ± 0.00 curvature change. CCH (Xiaflex) has Phase 3 RCTs with 832 patients and is FDA-approved (Gelbard 2013). RestoreX traction has positive RCT data (Ziegelmann 2019). Schedule matters too: any treatment delivered outside its published protocol has no evidence base for that schedule.
Your situation
Research finds
Source
Verapamil injection
Only double-blind RCT (Favilla 2017): 0.00° ± 0.00 curvature change. Every controlled trial of intralesional verapamil is negative. Major guidelines split: AUA conditional ("evidence weak"); EAU against; ICSM conditional.
Favilla 2017 (n=140)
Verapamil at non-standard interval (monthly+)
Published protocols use weekly to biweekly intervals. No published protocol uses intervals longer than monthly — controlled or uncontrolled.
Two Phase 3 double-blind RCTs (n=832): -17° vs placebo -9.3° (P<0.0001). FDA-approved specifically for PD. Fewer than half of patients achieve clinically meaningful improvement (46% composite responder).
Gelbard 2013 (IMPRESS)
RestoreX traction
RCT (n=100): -11.7° at 30-90 min/day × 3 months. Strongest single predictor of CCH improvement (+19.5°, multivariate P=.02). No prescription required. ICSM 2024 Conditional Recommendation.
Ziegelmann 2019; Cahill 2025; ICSM 2024
No active treatment / observation
Under-50 age cohort: 68% surgical rate (more aggressive progression than older patients).
Grasso 2007 (n=110)
Care History — what each item means
Each “no” or “unsure” in Section B is an opening for an evidence-grounded conversation. Here’s what to ask and why.
1
Was volume-loss / hourglass / indentation formally assessed at your Doppler?
65% of PD patients have one of these features (Margolin 2018, n=128) — and they predict BETTER CCH response, not worse (Cahill 2025, P=.02). If your Doppler didn't formally assess for them, you might be missing a feature that favors your treatment options.
2
Was calcification graded (stippled / dense / absent)?
Even if calcification is present, it does NOT reliably predict CCH failure (Cahill 2025, n=826, P=.37). The grading is worth documenting for completeness, but it should not be used to rule CCH out.
3
Did your provider discuss treatment alternatives (CCH, HA, traction, surgery)?
Only 60% of urologists do thorough pre-treatment assessment with in-office curvature measurement — and there's a significant difference between fellowship-trained vs non-fellowship-trained providers on this measure (Brant 2023, n=145; P=.003). A treatment recommendation given without options discussion may not meet the standard for informed consent.
4
If imaging was done elsewhere, was it accepted?
Outside-imaging refusal is a documented systemic pattern across medical specialties — sometimes driven by clinical reasons, sometimes by billing capture and scheduling control. For active-phase PD, every month of delay is a month of potential progression.
5
Does your provider's verbal explanation match the written report?
Verbal clinical communication often diverges from formal documentation — this is a recognized quality concern across all medical specialties. Treatment decisions should be based on documented findings, not verbal impressions.
6
Are your appointments at least 10 minutes?
Meaningful informed consent for a complex condition like PD — multiple treatments, phase-dependent selection, evidence-graded guidelines — is structurally impossible in a 3-minute encounter. Encounter length is a calibration of whether informed consent is operationally possible.
7
Was a modeling / traction / vacuum protocol prescribed alongside any injection?
Across multiple CCH studies, mechanical adjunct (modeling + traction) appears to be a necessary component of curvature correction. Studies with intensive multimodal mechanical adjunct (Capece 2018, n=135) report higher response rates than studies with standard modeling alone (IMPRESS Phase III, 46% composite responder). An injectable without mechanical adjunct may be missing the mechanism that produces curvature change.
8
Has your provider engaged with recent (post-2017) evidence?
21% of US urologists currently use AUA-discouraged treatments (Brant 2023, n=145). If your provider's answer references studies from before 2015, or they're unfamiliar with the Favilla 2017 verapamil RCT or the IMPRESS / Cahill 2025 CCH outcomes data, the conversation may not be happening on the current evidence base.
9
Is your provider fellowship-trained in andrology / sexual medicine?
81% of urologists treating PD have no fellowship in this area (Brant 2023, n=145). Across every measured evidence-based PD practice — in-office curvature assessment, duplex ultrasound, CCH use, traction recommendation, volume-loss assessment — fellowship-trained physicians are significantly more likely to apply current evidence (P<0.005 for all). This is the strongest cross-cutting predictor of evidence-based PD care.
Practice gaps to bring up
Patterns we’ve seen in real PD care that don’t match current evidence. Each gap has an “Ask” line you can use directly.
1
Calcification treated as CCH disqualifier despite n=826 contradicting evidence
Many urologists still rule out CCH for calcified plaques based on older guidance, but the largest published outcomes study (n=826) found no significant association between calcification and treatment failure. If you've been told CCH isn't an option because of calcification, this evidence is worth raising.
Ask:Is your decision to rule out CCH based on calcification consistent with the Cahill 2025 multicenter findings?
Routine PD evaluations often don't formally assess for hourglass narrowing, indentation, or distal tapering — yet 65% of patients have one of these (Margolin 2018), and moderate-to-severe hourglass actually predicts more CCH improvement.
Ask:Have you formally assessed me for hourglass deformity or indentation? If I have one, does that affect treatment selection?
Verapamil prescribed despite zero double-blind RCT efficacy
Intralesional verapamil is one of the most-prescribed PD treatments, yet the only double-blind RCT (Favilla 2017) found 0.00° ± 0.00 curvature change in the verapamil arm. Patients are rarely told this.
Ask:What controlled curvature evidence supports the protocol you're using? Are alternatives like CCH or RestoreX evidence-based options for me?
Active phase incorrectly used to defer all treatment
Some patients in active phase are told to wait for stability before any intervention — but Cahill 2025 (n=826) found phase was NOT a significant predictor of CCH outcome (P=.48). Active phase rules out surgery, not CCH.
Ask:Is being in active phase actually a barrier to CCH for me, or only to surgery?
5
Doppler not always performed before treatment recommendation
Vascular Doppler resolves whether erectile difficulty is vascular, PD-secondary, or psychogenic — yet many patients receive treatment recommendations without one. 56.4% of PD patients with ED had ED before PD developed (Paulis 2024), so the cause matters.
Ask:Have I had a vascular Doppler? If not, can we do one before deciding on treatment?
6
Pain reduction confused with disease stability
"Your pain is going away, you're stabilizing" is a common but incorrect inference. ICSM 2024 explicitly states pain reduction does NOT confirm phase stability — only stable curvature measurement does.
Ask:Are you determining my phase by pain trajectory, curvature measurement, or both?
7
Non-standard injection intervals without published protocol basis
Verapamil published protocols use weekly to biweekly intervals; some clinicians extend to 3 months or longer with no published evidence base. If the protocol isn't on the published map, the outcome isn't on the published map either.
Ask:What's the published protocol you're following? Are the intervals you're using consistent with the studies you're citing?
PD is associated with depression and relationship distress, yet mental-health screening is rarely part of the routine PD visit. The psychological burden is part of the disease, not a separate problem to handle later.
Ask:Do you screen for depression or relationship impact as part of PD care, or refer for that separately?
Questions you might want to ask
First — Get Information
1. “I'm noticing distinct thinning in the upper third with a clear restriction. Can you assess for hourglass deformity, indentation, and axial instability? I've read that this may actually predict better Xiaflex response.”
65% of PD patients have volume-loss deformities (Margolin 2018, n=128). Often overlooked. Cahill 2025 (n=826, multivariate P=.02) — moderate/severe hourglass/indentation predicts 3-10° MORE CCH improvement.
2. “My March Doppler didn't characterize calcification. Can you grade it — stippled or dense?”
Worth documenting for baseline. However, Cahill 2025 (n=826, P=.37) shows calcification is NOT a reliable predictor of CCH failure — CCH remains viable regardless of calcification status.
3. “My March Doppler showed 40° dorsal. Can you measure today and compare? I'm noticing visible progression. Am I in stable phase — and how are you determining that: curvature measurement, pain, or both?”
Pain alone is NOT a reliable stability indicator (ICSM 2024, Trost 2024). Curvature stability ≥3 months is the criterion. Phase determines treatment options.
Then — Test Whether They're Current
4. “I've been on verapamil at 3-month intervals. Published protocols use weekly to biweekly. The only double-blind RCT showed zero curvature change. What's your assessment?”
Favilla 2017, n=140, double-blind: verapamil 0.00° ± 0.00. AUA calls verapamil evidence "weak" with "clearly more effective" alternatives. CUA is the only society that recommends it (Level 3, Grade C — practice-based).
5. “Given my 40° dorsal curvature and normal vascular flow, would I be a candidate for Xiaflex with RestoreX traction? Cahill 2025 shows RestoreX is the strongest predictor of CCH improvement.”
Dorsal responds best: 50% median improvement (Lumbiganon 2025, n=292). RestoreX: 19.5° greater improvement on multivariate (Cahill 2025, P=.02, strongest predictor). 6.9× more likely ≥20° improvement (Alom 2019). Confound: 98% used RestoreX — cannot fully separate from concurrent protocol changes.
If
6. “Are you familiar with intralesional hyaluronic acid for PD? Two double-blind RCTs show it outperforms verapamil — with no significant or lasting adverse events reported.”
Favilla 2017: HA -4.6° vs V 0.0°. Abdel Fattah 2024: HA -9.4° vs V -5.4°. BUT: EAU 2026 and ICSM 2024 both recommend against HA outside clinical trials. Approved only in Italy.
If they say… the evidence says
"60% of my verapamil patients improve"
Uncontrolled data. Only double-blind RCT (Favilla 2017, n=140): zero change.
"Let's keep going with verapamil"
No published protocol uses 3-month intervals. Disease is progressing on it.
"Wait and see"
You're 41. Under-50 cohort: 68% worsened and required surgery (Grasso 2007, n=110). Active phase is NOT a barrier to CCH: Cahill 2025 (P=.48, NS) and Cocci 2020 (-19.3°, n=74). Waiting = progression.
"Consider stem cells or PRP"
ICSM 2024 Strong Recommendation against. "No convincing evidence."
"Try interferon injections"
IFN alpha-2B is no longer commercially available as of 2024.
"ESWT will help curvature"
ALL major guidelines: ESWT for pain ONLY, NOT curvature. AUA: "overall utility is low."
"Surgery now"
Requires stable phase ≥6 months (ICSM 2024). If still progressing, surgery is premature.
